Evidence map›Paper›PMID 42381179›Full record

ArticleThoracic cancer2026

Transformation or Clonal Evolution? A Rare Case Report of Pulmonary Sarcomatoid Carcinoma Developing to Small Cell Lung Cancer.

Wen Jiang, Yuwei Zhang, Xingmei Li, Qi Si, Zhaohuan Ye, Youfeng Ma, Haitao Zhou, Jianwei Huang, Chao Zhang, Ge Zhang

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Thoracic cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Wen JiangHenan Medical University, Xinxang, Henan, China.ORCID https://orcid.org/0009-0006-3797-2905
Yuwei ZhangDepartment of Respiratory Medicine, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang, Henan, China.ORCID https://orcid.org/0009-0000-8043-1676
Xingmei LiDepartment of Respiratory Medicine, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang, Henan, China.
Qi SiDepartment of Gastroenterology, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang, Henan, China.ORCID https://orcid.org/0009-0001-5481-737X
Zhaohuan YeDepartment of Respiratory Medicine, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang, Henan, China.ORCID https://orcid.org/0009-0008-9094-0077
Youfeng MaDepartment of Respiratory Medicine, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang, Henan, China.
Haitao ZhouHenan International Joint Laboratory of Tumor Cell Immunity and Regenerative Medicine, Henan Province Engineering Research Center for Multi-Omics Precision Diagnosis and Treatment of Pulmonary Diseases, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang, Henan, China.
Jianwei HuangDepartment of Pathology, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang, Henan, China.
Chao ZhangDepartment of Thoracic Surgery, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang, Henan, China.
Ge ZhangHenan International Joint Laboratory of Tumor Cell Immunity and Regenerative Medicine, Henan Province Engineering Research Center for Multi-Omics Precision Diagnosis and Treatment of Pulmonary Diseases, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang, Henan, China.ORCID https://orcid.org/0000-0002-2576-335X

Funding

Henan Province Engineering Research Center of Pulmonary Diseases Multi-omics Precision Diagnosis and Treatment DZXGCZXYN01Henan Province Engineering Research Center of Pulmonary Diseases Multi-omics Precision Diagnosis and Treatment DZXGCZXYN04Henan Province Joint Fund for Science and Technology Research and Development Program 252103810351Henan Province Science and Technology Research Program 232102310108Henan Province Science and Technology Research Program 252102310270Henan Province Science and Technology Research Program LHGJ20230816Henan Province Science and Technology Research Program LHGJ20230828Luoyang Key Medical and Health Projects 2302009AShanghai Guokang Targeted Traditional Chinese Medicine Research Institute SHGK2021ZS001Shanghai Guokang Targeted Traditional Chinese Medicine Research Institute SHGK2022ZS001State Key Laboratory of Neurology and Oncology Drug Development SKLSIM-20250437
6 · The paper itself

Abstract

Many cases of non-small cell lung cancer (NSCLC) transforming to small cell lung cancer (SCLC) after targeted therapy have been reported, most of which are associated with acquired resistance mutations. Herein, we report the first documented case of phenotypic conversion to SCLC in a patient with advanced pulmonary sarcomatoid carcinoma (PSC) who received pemetrexed, carboplatin, and camrelizumab only, with no targeted agents administered. Through comparative analysis of two serial pathological biopsies and genetic profiling, our findings suggest that PSC may undergo clonal evolution or alternative transformation mechanisms under therapeutic pressure. TP53 and RET mutations may be implicated in this phenotypic transition. This case provides new insights into the biological mechanism underlying the evolution of PSC to SCLC.

Indexed as

Cell Transformation, NeoplasticClonal EvolutionLung NeoplasmsSmall Cell Lung CarcinomaHumansMalepulmonary sarcomatoid carcinomaRETsmall cell lung cancerTP53tumor heterogeneity

Identifiers

PMID42381179
PMCPMC13318924

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.